Reconstructive Surgery at Hysterectomy for Patients With Uterine Prolapse and Gynecologic Malignancy.

Obstetrics and gynecology 2023 Vol.142(6) p. 1487-1490

Deshpande RR, Foy OB, Mandelbaum RS, Roman LD, Dancz CE, Wright JD, Matsuo K

Abstract

In this cross-sectional study examining 211,708 patients with a diagnosis of uterine prolapse who underwent hysterectomy between 2016 and 2019 identified in the Healthcare Cost and Utilization Project's Nationwide Ambulatory Surgery Sample, co-diagnosis of gynecologic malignancy was reported in 2,398 (1.1%) patients, and they were less likely to receive reconstructive surgery at hysterectomy (odds ratio [OR] 0.90, 95% CI 0.84-0.96). This absence of reconstructive surgery was most pronounced among patients with complete uterine prolapse and gynecologic malignancy (OR 0.68, 95% CI 0.57-0.81). The association was also consistent in coexisting gynecologic premalignancy (n=3,357 [1.6%]). In conclusion, this national-level assessment suggests that patients with uterine prolapse and coexisting gynecologic malignancy or premalignancy may be less likely to receive reconstructive surgery for pelvic floor dysfunction at hysterectomy.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
해부 Uterine scispacy 1
약물 [1.6%]) scispacy 1
질환 Uterine Prolapse C0042140
Uterine Prolapse
scispacy 1
질환 Malignancy C0006826
Malignant Neoplasms
scispacy 1
질환 co-diagnosis scispacy 1
질환 pelvic floor dysfunction C4041537
Pelvic floor dysfunction
scispacy 1

MeSH Terms

Humans; Female; Uterine Prolapse; Gynecologic Surgical Procedures; Genital Neoplasms, Female; Cross-Sectional Studies; Surgery, Plastic; Hysterectomy; Pelvic Organ Prolapse